117 related articles for article (PubMed ID: 37579970)
1. Inhibiting Wnt Signaling Reduces Cholestatic Injury by Disrupting the Inflammatory Axis.
Ayers M; Kosar K; Xue Y; Goel C; Carson M; Lee E; Liu S; Brooks E; Cornuet P; Oertel M; Bhushan B; Nejak-Bowen K
Cell Mol Gastroenterol Hepatol; 2023; 16(6):895-921. PubMed ID: 37579970
[TBL] [Abstract][Full Text] [Related]
2. β-Catenin regulation of farnesoid X receptor signaling and bile acid metabolism during murine cholestasis.
Thompson MD; Moghe A; Cornuet P; Marino R; Tian J; Wang P; Ma X; Abrams M; Locker J; Monga SP; Nejak-Bowen K
Hepatology; 2018 Mar; 67(3):955-971. PubMed ID: 28714273
[TBL] [Abstract][Full Text] [Related]
3. Wnt/β-Catenin Signaling Plays a Protective Role in the Mdr2 Knockout Murine Model of Cholestatic Liver Disease.
Pradhan-Sundd T; Kosar K; Saggi H; Zhang R; Vats R; Cornuet P; Green S; Singh S; Zeng G; Sundd P; Nejak-Bowen K
Hepatology; 2020 May; 71(5):1732-1749. PubMed ID: 31489648
[TBL] [Abstract][Full Text] [Related]
4. Activation of WNT/Beta-Catenin Signaling and Regulation of the Farnesoid X Receptor/Beta-Catenin Complex After Murine Bile Duct Ligation.
Zhang R; Nakao T; Luo J; Xue Y; Cornuet P; Oertel M; Kosar K; Singh S; Nejak-Bowen K
Hepatol Commun; 2019 Dec; 3(12):1642-1655. PubMed ID: 31832572
[TBL] [Abstract][Full Text] [Related]
5. Wedelolactone alleviates cholestatic liver injury by regulating FXR-bile acid-NF-κB/NRF2 axis to reduce bile acid accumulation and its subsequent inflammation and oxidative stress.
Wang MQ; Zhang KH; Liu FL; Zhou R; Zeng Y; Chen AL; Yu Y; Xia Q; Zhu CC; Lin CZ
Phytomedicine; 2024 Jan; 122():155124. PubMed ID: 38014837
[TBL] [Abstract][Full Text] [Related]
6. Boosting mitochondria activity by silencing MCJ overcomes cholestasis-induced liver injury.
Iruzubieta P; Goikoetxea-Usandizaga N; Barbier-Torres L; Serrano-Maciá M; Fernández-Ramos D; Fernández-Tussy P; Gutiérrez-de-Juan V; Lachiondo-Ortega S; Simon J; Bravo M; Lopitz-Otsoa F; Robles M; Ferre-Aracil C; Varela-Rey M; Elguezabal N; Calleja JL; Lu SC; Milkiewicz M; Milkiewicz P; Anguita J; Monte MJ; Marin JJG; López-Hoyos M; Delgado TC; Rincón M; Crespo J; Martínez-Chantar ML
JHEP Rep; 2021 Jun; 3(3):100276. PubMed ID: 33997750
[TBL] [Abstract][Full Text] [Related]
7. The role of sphingosine 1-phosphate receptor 2 in bile-acid-induced cholangiocyte proliferation and cholestasis-induced liver injury in mice.
Wang Y; Aoki H; Yang J; Peng K; Liu R; Li X; Qiang X; Sun L; Gurley EC; Lai G; Zhang L; Liang G; Nagahashi M; Takabe K; Pandak WM; Hylemon PB; Zhou H
Hepatology; 2017 Jun; 65(6):2005-2018. PubMed ID: 28120434
[TBL] [Abstract][Full Text] [Related]
8. PGC1α deficiency reverses cholestasis-induced liver injury via attenuating hepatic inflammation and promoting bile duct remodeling.
Li D; Ye C; Liu P; Sun T; Qin Y; Wan X
Acta Histochem; 2023 Dec; 125(8):152097. PubMed ID: 37813066
[TBL] [Abstract][Full Text] [Related]
9. Probiotic Lactobacillus rhamnosus GG Prevents Liver Fibrosis Through Inhibiting Hepatic Bile Acid Synthesis and Enhancing Bile Acid Excretion in Mice.
Liu Y; Chen K; Li F; Gu Z; Liu Q; He L; Shao T; Song Q; Zhu F; Zhang L; Jiang M; Zhou Y; Barve S; Zhang X; McClain CJ; Feng W
Hepatology; 2020 Jun; 71(6):2050-2066. PubMed ID: 31571251
[TBL] [Abstract][Full Text] [Related]
10. Systemic ASBT inactivation protects against liver damage in obstructive cholestasis in mice.
Kunst RF; de Waart DR; Wolters F; Duijst S; Vogels EW; Bolt I; Verheij J; Beuers U; Oude Elferink RPJ; van de Graaf SFJ
JHEP Rep; 2022 Nov; 4(11):100573. PubMed ID: 36160754
[TBL] [Abstract][Full Text] [Related]
11. Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease.
Blokker BA; Maijo M; Echeandia M; Galduroz M; Patterson AM; Ten A; Philo M; Schungel R; Gutierrez-de Juan V; Halilbasic E; Fuchs C; Le Gall G; Milkiewicz M; Milkiewicz P; Banales JM; Rushbrook SM; Mato JM; Trauner M; Müller M; Martínez-Chantar ML; Varela-Rey M; Beraza N
Hepatology; 2019 Feb; 69(2):699-716. PubMed ID: 30229970
[TBL] [Abstract][Full Text] [Related]
12. Wnt-Signaling Inhibitor Wnt-C59 Suppresses the Cytokine Upregulation in Multiple Organs of Lipopolysaccharide-Induced Endotoxemic Mice via Reducing the Interaction between β-Catenin and NF-κB.
Jang J; Song J; Sim I; Kwon YV; Yoon Y
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200709
[TBL] [Abstract][Full Text] [Related]
13. Loss of apical sodium bile acid transporter alters bile acid circulation and reduces biliary damage in cholangitis.
Meadows V; Marakovits C; Ekser B; Kundu D; Zhou T; Kyritsi K; Pham L; Chen L; Kennedy L; Ceci L; Wu N; Carpino G; Zhang W; Isidan A; Meyer A; Owen T; Gaudio E; Onori P; Alpini G; Francis H
Am J Physiol Gastrointest Liver Physiol; 2023 Jan; 324(1):G60-G77. PubMed ID: 36410025
[TBL] [Abstract][Full Text] [Related]
14. Deleterious effect of oltipraz on extrahepatic cholestasis in bile duct-ligated mice.
Weerachayaphorn J; Luo Y; Mennone A; Soroka CJ; Harry K; Boyer JL
J Hepatol; 2014 Jan; 60(1):160-6. PubMed ID: 23978715
[TBL] [Abstract][Full Text] [Related]
15. Mast Cells Regulate Ductular Reaction and Intestinal Inflammation in Cholestasis Through Farnesoid X Receptor Signaling.
Meadows V; Kennedy L; Ekser B; Kyritsi K; Kundu D; Zhou T; Chen L; Pham L; Wu N; Demieville J; Hargrove L; Glaser S; Alpini G; Francis H
Hepatology; 2021 Nov; 74(5):2684-2698. PubMed ID: 34164827
[TBL] [Abstract][Full Text] [Related]
16. BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination.
Jung H; Chen J; Hu X; Sun H; Wu SY; Chiang CM; Kemper B; Chen LF; Kemper JK
JCI Insight; 2020 Dec; 6(1):. PubMed ID: 33290278
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of CBP/β-catenin signaling ameliorated fibrosis in cholestatic liver disease.
Kimura M; Nishikawa K; Osawa Y; Imamura J; Yamaji K; Harada K; Yatsuhashi H; Murata K; Miura K; Tanaka A; Kanto T; Kohara M; Kamisawa T; Kimura K
Hepatol Commun; 2022 Oct; 6(10):2732-2747. PubMed ID: 35855613
[TBL] [Abstract][Full Text] [Related]
18. Sortilin 1 Loss-of-Function Protects Against Cholestatic Liver Injury by Attenuating Hepatic Bile Acid Accumulation in Bile Duct Ligated Mice.
Li J; Woolbright BL; Zhao W; Wang Y; Matye D; Hagenbuch B; Jaeschke H; Li T
Toxicol Sci; 2018 Jan; 161(1):34-47. PubMed ID: 28453831
[TBL] [Abstract][Full Text] [Related]
19. Hepatocyte specific expression of an oncogenic variant of β-catenin results in cholestatic liver disease.
Lemberger UJ; Fuchs CD; Karer M; Haas S; Stojakovic T; Schöfer C; Marschall HU; Wrba F; Taketo MM; Egger G; Trauner M; Österreicher CH
Oncotarget; 2016 Dec; 7(52):86985-86998. PubMed ID: 27895309
[TBL] [Abstract][Full Text] [Related]
20. Network pharmacology-based mechanism prediction and pharmacological validation of Xiaoyan Lidan formula on attenuating alpha-naphthylisothiocyanate induced cholestatic hepatic injury in rats.
Wang M; Liu F; Yao Y; Zhang Q; Lu Z; Zhang R; Liu C; Lin C; Zhu C
J Ethnopharmacol; 2021 Apr; 270():113816. PubMed ID: 33444723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
